LCLS LLRF UPGRADES TO THE SLAC LINAC*

The Linac Coherent Light Source (LCLS) at SLAC will be the brightest X-ray laser in the world when it comes on line. In order to achieve the brightness a 200fS length electron bunch is passed through an undulator. To create the 200fS, 3kA bunch, a 10pS electron bunch, created from a photo cathode in an RF gun, is run off crest on the RF to set up a position to energy correlation. The bunch is then compressed by chicanes. The stability of the RF system is critical in setting up the position to energy correlation. Specifications derived from simulations require the RF system to be stable to below 200fS in several critical injector stations and the last kilometer of linac. The SLAC linac RF system is being upgraded to meet these requirements. used to accelerate the beam to 4.3GeV before entering BC2. Linac 3, klystron stations 25-1 to 30-8, accelerates the beam to 13.6GeV

Coherent Transition Radiation to Measure the SLAC Electron Bunch Length

Coherent transition radiation is used to measure the length of the ultra-short electron bunches available at the Stanford Linear Accelerator Center. The results and the limitations of the method are described

Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma

Daratumumab, a human CD38 immunoglobulin G1 kappa (IgG1κ) monoclonal antibody, has activity as monotherapy in multiple myeloma (MM). This phase 1/2 study investigated daratumumab plus lenalidomide/dexamethasone in refractory and relapsed/refractory MM. Part 1 (dose escalation) evaluated 4 daratumumab doses plus lenalidomide (25 mg/day orally on days 1-21 of each cycle) and dexamethasone (40 mg/week). Part 2 (dose expansion) evaluated daratumumab at the recommended phase 2 dose (RP2D) plus lenalidomide/dexamethasone. Safety, efficacy, pharmacokinetics, immunogenicity, and accelerated daratumumab infusions were studied. In part 1 (13 patients), no dose-limiting toxicities were observed, and 16 mg/kg was selected as the R2PD. In part 2 (32 patients), median time since diagnosis was 3.2 years, with a median of 2 prior therapies (range, 1-3 prior therapies), including proteasome inhibitors (91%), alkylating agents (91%), autologous stem cell transplantation (78%), thalidomide (44%), and lenalidomide (34%); 22% of patients were refractory to the last line of therapy. Grade 3 to 4 adverse events (≥5%) included neutropenia, thrombocytopenia, and anemia. In part 2, infusion-related reactions (IRRs) occurred in 18 patients (56%); most were grade ≤2 (grade 3, 6.3%). IRRs predominantly occurred during first infusions and were more common during accelerated infusions. In part 2 (median follow-up of 15.6 months), overall response rate was 81%, with 8 stringent complete responses (25%), 3 complete responses (9%), and 9 very good partial responses (28%). Eighteen-month progression-free and overall survival rates were 72% (95% confidence interval, 51.7-85.0) and 90% (95% confidence interval, 73.1-96.8), respectively. Daratumumab plus lenalidomide/dexamethasone resulted in rapid, deep, durable responses. The combination was well tolerated and consistent with the safety profiles observed with lenalidomide/dexamethasone or daratumumab monotherapy. This trial was registered at www.clinicaltrials.gov as #NCT01615029

Photoinjector design for the LCLS

The design of the Linac Coherent Light Source assumes that a low-emittance, 1-nC, 10-ps beam will be available for injection into the 15-GeV linac. The proposed rf photocathode injector that will provide a 150-MeV beam with rms normalized emittances of 1 mm in both the transverse and longitudinal dimensions is based on a 1.6-cell S-band rf gun that is equipped with an emittance compensating solenoid. The booster accelerator is positioned at the beam waist coinciding with the first emittance maximum and is provided with an accelerating gradient of ~25 MeV/m, i.e., the "new working point." The uv pulses required for cathode excitation will be generated by tripling the output of a Ti:sapphire laser system consisting of a highly stable cw mode-locked oscillator and two bow-tie amplifiers pumped by a pair of Q-switched Nd:YAG lasers. The large bandwidth of the Ti:sapphire system accommodates the desired temporal pulse shaping. Details of the design and the supporting simulations are presented.Comment: 13 pages (double spaced), 4 figures, contributed to The 23rd International Free Electron Laser Conference, Darmstadt, Germany, 20-24 August 200

Measured Emittance versus Store Time in the SLC Damping Ring

Emittance studies at the SLC North Damping Ring led to precise measurements of the damping time using three independent methods. These measurements were done at three different locations: (1) in the ring using a fast gated video camera which allows the acquisition of the image of the synchrotron light from a single turn, (2) using the extracted beam and a single wire scanner in the ring-to-linac transport line, and (3) in the linac using four wire scanners. In addition the extracted beam emittance was studied as a function of various parameters. A significant dependence on the tune was observed